Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Chardan Capital
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24 ...
FierceBiotech4d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Seeking Alpha8d
PERCF Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen ...
Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement
Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...
PharmiWeb3d
RNA Therapeutics Market Outlook 2034 | Industry Report
Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...
Yahoo Finance3d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
An investigational antisense oligonucleotide ... 70% of external clinical development costs for the therapy. Stoke Therapeutics CEO Edward Kaye stated: “With Biogen’s deep experience in ...